E88.12
Generalized lipodystrophy
Clinical Classification Guidelines
Inclusion Terms
- Acquired generalized lipodystrophy (AGL)
- Berardinelli-Siep syndrome
- Congenital generalized lipodystrophy (CGL)
- Lawrence syndrome
Medical Intelligence & Overview
Generalized lipodystrophy is a rare condition characterized by the loss of fat tissue throughout the body. This condition can be either acquired or present from birth, affecting how the body stores and manages fat. Due to the absence of fat tissue, individuals may experience a range of health issues related to metabolism and body composition. The condition includes different forms such as congenital generalized lipodystrophy (CGL), also known as Berardinelli-Siep syndrome, and acquired generalized lipodystrophy (AGL), sometimes referred to as Lawrence syndrome.
Causes & Symptoms
Clinical Causes: Genetic mutations inherited from parents, leading to congenital forms like CGL Autoimmune responses that cause fat tissue loss in acquired forms Unknown factors may contribute in some cases Other medical conditions or treatments that can result in fat tissue loss Environmental factors are rarely involved in the development
Key Symptoms: Increased muscular appearance due to lack of fat covering muscles Enlarged liver and spleen (hepatosplenomegaly) High levels of triglycerides and other fats in the blood Insulin resistance or diabetes mellitus Muscle hypertrophy and prominent veins Absence of subcutaneous fat in the face, limbs, and trunk Development of acanthosis nigricans (darkened skin patches) Delayed or abnormal wound healing Possible early onset of cardiovascular problems
Diagnostic & Treatment
Diagnosis Path: The diagnosis involves a combination of clinical evaluation, medical history, and laboratory tests. Healthcare providers may use imaging techniques like MRI or CT scans to assess fat tissue distribution. Blood tests often reveal abnormal lipid profiles and elevated blood sugar levels. Genetic testing can identify mutations responsible for congenital forms. A thorough physical examination will note characteristic loss of subcutaneous fat and associated features.
Treatment Protocols: While there is no cure for generalized lipodystrophy, management focuses on controlling associated health problems. Treatment options may include:
Clinical Advice & FAQs
Billing Guidance
Is E88.12 a billable ICD-10 code?
Yes, E88.12 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E88.12?
Clinical documentation must specify the nature of Generalized lipodystrophy and any associated comorbidities for accurate reporting.
Cite this Clinical Reference